title: The safety and effect of chemotherapy with short hydration for urothelial cancer on patients' quality of life.
abstract: OBJECTIVE
  Our aim was 2-fold: first, to assess the safety of short hydration treatment for urothelial cancer; and second, to assess the resultant quality of life of patients who received the treatment.
  
  
  METHODS
  We assessed 61 patients including 31 outpatients and 30 inpatients, who received a combination of gemcitabine and cisplatin chemotherapy with short hydration. The serum creatinine (Cr) level and the estimated glomerular filtration rate were measured to assess renal function using linear mixed model analysis. To assess quality of life, the patients were asked to respond to the Functional Assessment of Cancer Therapy-General questionnaire. The responses were then analyzed using the paired t-test.
  
  
  RESULTS
  Patients who received short hydration chemotherapy showed no significant change in serum Cr level (P = 0.423) or estimated glomerular filtration rate  (P = 0.582). There was also no significant change in serum Cr level or estimated glomerular filtration rate between patients who received short hydration chemotherapy and those who received consecutive hydration chemotherapy (P = 0.154 and 0.311, respectively). In every patient, the Functional Assessment of Cancer Therapy-General total score and subscale scores both improved as a result of outpatient chemotherapy with short hydration (P < 0.01).
  
  
  CONCLUSIONS
  The short hydration gemcitabine and cisplatin regimen for patients with urothelial cancer was safe. Further, the outpatient chemotherapy was found not only to be safe, but also to have improved the patients' quality of life.
authors.affiliation: Department of Urology, Tokyo Metropolitan Tama Medical Center, 2-9-2 Musashidai, Fuchu, Tokyo 183-0042, Japan tazuma-tky@umin.ac.jp.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Azuma
authors.affiliation: Department of Urology, Tokyo Metropolitan Tama Medical Center, 2-9-2 Musashidai, Fuchu, Tokyo 183-0042, Japan.
authors.forename: Yukihide
authors.initials: Y
authors.lastname: Matayoshi
authors.affiliation: Department of Urology, Tokyo Metropolitan Tama Medical Center, 2-9-2 Musashidai, Fuchu, Tokyo 183-0042, Japan.
authors.forename: Yujiro
authors.initials: Y
authors.lastname: Sato
authors.affiliation: Department of Urology, Tokyo Metropolitan Tama Medical Center, 2-9-2 Musashidai, Fuchu, Tokyo 183-0042, Japan.
authors.forename: Yohsuke
authors.initials: Y
authors.lastname: Sato
authors.affiliation: Department of Urology, Tokyo Metropolitan Tama Medical Center, 2-9-2 Musashidai, Fuchu, Tokyo 183-0042, Japan.
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Nagase
authors.affiliation: Department of Urology, Tokyo Metropolitan Tama Medical Center, 2-9-2 Musashidai, Fuchu, Tokyo 183-0042, Japan.
authors.forename: Masaya
authors.initials: M
authors.lastname: Oshi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002945:Cisplatin / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005440:Fluid Therapy; D005919:Glomerular Filtration Rate; D006801:Humans; D007668:Kidney / Q000503:physiopathology; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D016896:Treatment Outcome; D014571:Urologic Neoplasms / Q000188:drug therapy*; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D003404:Creatinine; D002945:Cisplatin; D000093542:Gemcitabine
keywords: chemotherapy; cisplatin; gemcitabine; short hydration; urothelial cancer